Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study

OBJECTIVE: In the Phase III PAOLA study (clinicaltrials.gov: NCT01137682), enrolled patients had uncontrolled acromegaly despite ≥6 months of octreotide/lanreotide treatment before study start. More patients achieved biochemical control with long-acting pasireotide versus continued treatment with oc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Endocrinol
Autors principals: Colao, Annamaria, Bronstein, Marcello D, Brue, Thierry, De Marinis, Laura, Fleseriu, Maria, Guitelman, Mirtha, Raverot, Gerald, Shimon, Ilan, Fleck, Jürgen, Gupta, Pritam, Pedroncelli, Alberto M, Gadelha, Mônica R
Format: Artigo
Idioma:Inglês
Publicat: Bioscientifica Ltd 2020
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7222286/
https://ncbi.nlm.nih.gov/pubmed/32217809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-19-0762
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars